HIGHLIGHTS
- who: Zhanying Hou from the Frontiers Media SA, SwitzerlandDepartment of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou have published the research: Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis, in the Journal: (JOURNAL)
SUMMARY
ACCEPTED baricitinib, JAK inhibitor, systemic sclerosis, skin fibrosis, digital ulcers CITATION Hou Z, Su X, Han G, Xue R, Chen Y, Chen Y, Wang H, Yang B, Liang Y and Ji S Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis. A corrigendum on JAK1/2 inhibitor baricitinib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.